Ticker League

EBITDA Margin for Bristol-Myers Squibb (BMY)

As of · Reported

Metric

TTM

28.4%

YoY change

+23.62pp

Trough year (2024)

6.6%

Peak year (2021)

43.4%

EBITDA Margin history chart for Bristol-Myers Squibb (BMY) from 1987 to 2025

Latest: 30.2%

EBITDA Margin change chart for Bristol-Myers Squibb (BMY) from 1987 to 2025

Latest: +23.62pp

EBITDA Margin history table for Bristol-Myers Squibb (BMY) from 1987 to 2025

  • 202530.2%+23.62pp
  • 20246.6%-36.47pp
  • 202343.0%+1.39pp
  • 202241.6%-1.73pp
  • 202143.4%+31.78pp
  • 202011.6%-16.62pp
  • 201928.2%-1.87pp
  • 201830.1%+0.65pp
  • 201729.4%-3.84pp
  • 201633.3%+17.35pp
  • 201515.9%-3.29pp
  • 201419.2%-4.30pp
  • 201323.5%+5.34pp
  • 201218.2%-18.32pp
  • 201136.5%+1.48pp
  • 201035.0%+0.50pp
  • 200934.5%+5.87pp
  • 200828.7%+5.81pp
  • 200722.8%+4.35pp
  • 200618.5%-5.80pp
  • 200524.3%-3.43pp
  • 200427.7%+0.34pp
  • 200327.4%+0.70pp
  • 200226.7%-3.61pp
  • 200130.3%-6.65pp
  • 200037.0%+7.70pp
  • 199929.3%+1.47pp
  • 199827.8%-2.32pp
  • 199730.1%+0.43pp
  • 199629.7%+0.17pp
  • 199529.5%-0.10pp
  • 199429.6%+5.86pp
  • 199323.8%+3.54pp
  • 199220.2%-6.78pp
  • 199127.0%+1.43pp
  • 199025.6%+11.64pp
  • 198913.9%-8.93pp
  • 198822.8%+1.30pp
  • 198721.5%—

EBITDA Margin values are taken from Bristol-Myers Squibb's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA Margin at Bristol-Myers Squibb (BMY)

According to Bristol-Myers Squibb's latest reported financial statements, the company's latest reported EBITDA margin is 28.4%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.

Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, Bristol-Myers Squibb (BMY) reported EBITDA margin of 30.18% – expanded 23.6 percentage points year-over-year.

The record annual EBITDA margin stands at 43.37%, reached in 2021; the historical low of 6.56% was recorded in 2024.

Bristol-Myers Squibb EBITDA Margin by Year

Bristol-Myers Squibb EBITDA Margin 2025: 30.2%

In 2025, Bristol-Myers Squibb reported EBITDA margin of 30.18%, expanded 23.6 percentage points from 2024.

Bristol-Myers Squibb EBITDA Margin 2024: 6.6%

Bristol-Myers Squibb EBITDA margin in 2024 was 6.56%, contracted 36.5 percentage points from 2023. This figure represents the lowest annual value in the available history.

Bristol-Myers Squibb EBITDA Margin 2023: 43.0%

2023's EBITDA margin for Bristol-Myers Squibb came in at 43.03%, expanded 1.4 percentage points from 2022.

Bristol-Myers Squibb EBITDA Margin 2022: 41.6%

Bristol-Myers Squibb posted EBITDA margin of 41.64% in 2022, contracted 1.7 percentage points from 2021.

Bristol-Myers Squibb EBITDA Margin 2021: 43.4%

Bristol-Myers Squibb EBITDA margin in 2021 was 43.37%.

See more financial history for Bristol-Myers Squibb (BMY).

Sector peers by EBITDA Margin

Healthcare peers of Bristol-Myers Squibb (BMY), ranked by their latest EBITDA margin

Frequently asked questions

Bristol-Myers Squibb (BMY) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview